Navigation Links
Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management
Date:9/11/2007

GenoTrim to play a role on the nation's obesity crisis by addressing

genetics associated with hunger and excess weight.

SAN DIEGO, Sept. 11 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company, announced the launch of GenoTrim, a DNA-based nutritional solution for weight management*. Attempts to achieve a healthy weight through both standard weight reduction strategies and numerous "gimmicks" have proven unsuccessful for the 58 million overweight individuals in the U.S. GenoTrim uniquely identifies specific genetic factors affecting hunger, metabolism and body composition that may contribute to the weight challenges of many of these individuals.

"GenoTrim tests for five key genes associated with the hereditary contributors to weight and hunger. From the genetic analysis, the individual is provided a nutrient formulation guided by their genetic profile," stated Lonna J. Williams, COO and SVP of Marketing at Salugen, Inc. Williams goes on to say, "GenoTrim is not a lose-weight-quick or magic pill. By addressing gene mutations inhibiting one's ability to manage weight, it provides a measure of control and help to break through obstacles encountered in previous weight loss efforts. Importantly, healthy eating and exercise are essential to proper weight management."

GenoTrim and its ingredients are supported by numerous published clinical studies including the award winning study Dietary Investigation to Evaluate Treatments (D.I.E.T.), lead by Dr. Ken Blum, Chief Scientific Officer of Salugen and a professor in the Department of Physiology and Pharmacology at Wake Forest University School of Medicine. Compared to most nutritional supplements, GenoTrim ingredient combinations have been proven in published, randomized, double-blinded placebo-controlled studies to result in weight loss. In three published clinical studies, GenoTrim resulted in an average weight loss of 12.8 lbs, 17.15 lbs and 26.96 lbs in as few as 8 weeks. Additionally, GenoTrim resulted in significant reductions in sugar cravings and appetite, as well as improvements in sleep and mood.*

Positive case studies have been received from among the 1500 pilot study participants. Additional prospective studies are ongoing. GenoTrim can be purchased through Salugen's distribution partner DNA Services of America or at http://www.GenoTrim.com .

About GenoTrim

GenoTrim is a DNA-customized nutritional solution for weight management. Based upon an analysis of five important genes effecting weight, GenoTrim ingredients and dosages are genetically-guided to address the underlying genetic factors involved in hormones and metabolism that Harvard Medical Experts suggest influence 70% to 80% of overweight cases. By addressing genetic factors that make individuals prone to weight problems, GenoTrim has demonstrated in studies to help reduce weight, appetite, sugar cravings, snacking, and late-night eating, as well as help support improved sleep, mood, and energy levels which results in sustainable weight loss. For more information on GenoTrim, please visit http://www.genotrim.com.

About Salugen

Salugen, Inc., a leading personalized health and wellness company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit http://www.salugen.com.

* These statements have not been evaluated by the U.S. Food and Drug

Administration. This product is not intended to diagnose, treat, cure or

prevent any disease.


'/>"/>
SOURCE Salugen
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):